U.S. Markets close in 38 mins
  • S&P 500

    3,667.23
    +4.78 (+0.13%)
     
  • Dow 30

    29,871.77
    +47.85 (+0.16%)
     
  • Nasdaq

    12,346.03
    -9.08 (-0.07%)
     
  • Russell 2000

    1,838.68
    +2.64 (+0.14%)
     
  • Crude Oil

    45.24
    +0.69 (+1.55%)
     
  • Gold

    1,833.10
    +14.20 (+0.78%)
     
  • Silver

    24.18
    +0.09 (+0.39%)
     
  • EUR/USD

    1.2102
    +0.0023 (+0.1936%)
     
  • 10-Yr Bond

    0.9480
    +0.0140 (+1.50%)
     
  • Vix

    20.85
    +0.08 (+0.39%)
     
  • GBP/USD

    1.3360
    -0.0063 (-0.4663%)
     
  • USD/JPY

    104.5200
    +0.2040 (+0.1956%)
     
  • BTC-USD

    19,051.34
    +57.44 (+0.30%)
     
  • CMC Crypto 200

    373.75
    +8.83 (+2.42%)
     
  • FTSE 100

    6,463.39
    +78.66 (+1.23%)
     
  • Nikkei 225

    26,800.98
    +13.44 (+0.05%)
     

Syndax Pharmaceuticals Inc (SNDX) President and COO Michael A Metzger Sold $2 million of Shares

GuruFocus.com
·1 min read

- By insider

President and COO of Syndax Pharmaceuticals Inc (30-Year Financial, Insider Trades) Michael A Metzger (insider trades) sold 100,000 shares of SNDX on 11/04/2020 at an average price of $20.31 a share. The total sale was $2 million.


Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Syndax Pharmaceuticals Inc has a market cap of $814.350 million; its shares were traded at around $20.97 with and P/S ratio of 511.44. GuruFocus has detected 3 severe warning signs with Syndax Pharmaceuticals Inc. .

Directors and Officers Recent Trades:

  • President and COO Michael A Metzger sold 100,000 shares of SNDX stock on 11/04/2020 at the average price of $20.31. The price of the stock has increased by 3.25% since.

For the complete insider trading history of SNDX, click here

.This article first appeared on GuruFocus.